Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL®, a ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

Decitabine plus venetoclax and ponatinib appeared safe and elicited responses in a phase 2 trial of patients with advanced phase CML.

Rong Lu, associate professor of stem cell biology and regenerative medicine, biomedical engineering, medicine, and gerontology at USC, and a Leukemia & Lymphoma Society Scholar Lu is also a member of ...

The security forces are investigating in order to arrest the “terrorists” behind the blast, it said. The army is engaged in ... Myanmar’s conflict-torn Rakhine state could face an imminent acute ...

Amanda Robbins, the command's psychologist, there are distinct differences between acute traumatic brain injuries and what is called long-term blast exposure or blast overpressure. Traumatic brain ...

According to Wilson and Col. Amanda Robbins, the command’s psychologist, there are distinct differences between acute traumatic brain injuries and what is called long-term blast exposure or blast ...